IN2014MN02101A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02101A IN2014MN02101A IN2101MUN2014A IN2014MN02101A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A IN 2101MUN2014 A IN2101MUN2014 A IN 2101MUN2014A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A
- Authority
- IN
- India
- Prior art keywords
- heart failure
- present
- chronic heart
- stable chronic
- procalcitonin
- Prior art date
Links
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 2
- 108010048233 Procalcitonin Proteins 0.000 abstract 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12163921 | 2012-04-12 | ||
| PCT/EP2013/057626 WO2013153177A1 (en) | 2012-04-12 | 2013-04-11 | Prognosis of adverse events in patients with suspected chronic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02101A true IN2014MN02101A (es) | 2015-08-28 |
Family
ID=48050768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2101MUN2014 IN2014MN02101A (es) | 2012-04-12 | 2013-04-11 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9488659B2 (es) |
| EP (1) | EP2836841B1 (es) |
| JP (1) | JP5945063B2 (es) |
| CN (1) | CN104303061B (es) |
| BR (1) | BR112014025189B1 (es) |
| IN (1) | IN2014MN02101A (es) |
| RU (1) | RU2672561C2 (es) |
| WO (1) | WO2013153177A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5945063B2 (ja) * | 2012-04-12 | 2016-07-05 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性心不全が疑われる患者における有害事象の予後 |
| EP2990800A1 (en) * | 2014-08-29 | 2016-03-02 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Neprilysin as heartfailure (HF) prognostic marker |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| US10368774B2 (en) * | 2015-07-30 | 2019-08-06 | Medtronic, Inc. | Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event |
| CN105929152B (zh) * | 2016-07-15 | 2018-06-26 | 安徽国科生物科技有限公司 | 一种用于降钙素原检测的智能检测仪 |
| AU2018216033B2 (en) * | 2017-02-06 | 2021-10-07 | Biotempt B.V. | Peptide modulators of the interaction between human C-peptide and human elastin receptor for therapeutic use |
| CN108931658A (zh) * | 2018-04-16 | 2018-12-04 | 上海交通大学医学院附属瑞金医院 | 用于诊断心力衰竭合并症及预后评估的血清标记物 |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| RU2766252C1 (ru) * | 2021-04-13 | 2022-02-10 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования риска смерти у больных с хронической сердечной недостаточностью с использованием эндогенного эритропоэтина сыворотки крови |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| DE19847690A1 (de) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| CN101029897A (zh) * | 2007-02-09 | 2007-09-05 | 深圳市新产业生物医学工程有限公司 | 一种降钙素原测试试剂盒及其测试方法 |
| DE102007009751A1 (de) * | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| EP2174143B1 (en) * | 2007-08-03 | 2011-06-22 | B.R.A.H.M.S GmbH | Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease |
| EP2101178A1 (en) | 2008-03-12 | 2009-09-16 | BRAHMS Aktiengesellschaft | Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes |
| RU2357250C1 (ru) * | 2007-12-10 | 2009-05-27 | Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" | Способ прогнозирования течения хронической сердечной недостаточности |
| CN105334330A (zh) | 2009-04-14 | 2016-02-17 | B.R.A.H.M.S有限公司 | 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估 |
| EP2284540A1 (en) * | 2009-07-31 | 2011-02-16 | BIOCRATES Life Sciences AG | Method of diagnosing organ failure |
| CN201886025U (zh) * | 2010-12-10 | 2011-06-29 | 四川迈克生物科技股份有限公司 | 一种快速定量检测降钙素原免疫层析试纸条 |
| JP5945063B2 (ja) * | 2012-04-12 | 2016-07-05 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性心不全が疑われる患者における有害事象の予後 |
-
2013
- 2013-04-11 JP JP2015504958A patent/JP5945063B2/ja active Active
- 2013-04-11 IN IN2101MUN2014 patent/IN2014MN02101A/en unknown
- 2013-04-11 RU RU2014145259A patent/RU2672561C2/ru active
- 2013-04-11 WO PCT/EP2013/057626 patent/WO2013153177A1/en not_active Ceased
- 2013-04-11 US US14/391,953 patent/US9488659B2/en active Active
- 2013-04-11 BR BR112014025189A patent/BR112014025189B1/pt active IP Right Grant
- 2013-04-11 CN CN201380019816.2A patent/CN104303061B/zh active Active
- 2013-04-11 EP EP13714980.3A patent/EP2836841B1/en active Active
-
2016
- 2016-07-15 US US15/211,802 patent/US9753039B2/en active Active
-
2017
- 2017-09-01 US US15/693,880 patent/US20170370940A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015515630A (ja) | 2015-05-28 |
| US9488659B2 (en) | 2016-11-08 |
| RU2672561C2 (ru) | 2018-11-16 |
| BR112014025189A2 (pt) | 2017-07-11 |
| WO2013153177A1 (en) | 2013-10-17 |
| JP5945063B2 (ja) | 2016-07-05 |
| HK1203611A1 (en) | 2015-10-30 |
| RU2014145259A (ru) | 2016-06-10 |
| CN104303061A (zh) | 2015-01-21 |
| BR112014025189B1 (pt) | 2020-04-07 |
| EP2836841B1 (en) | 2022-01-05 |
| US20170370940A1 (en) | 2017-12-28 |
| US20150079696A1 (en) | 2015-03-19 |
| EP2836841A1 (en) | 2015-02-18 |
| US9753039B2 (en) | 2017-09-05 |
| US20160320411A1 (en) | 2016-11-03 |
| CN104303061B (zh) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014025189A2 (pt) | prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| MX339427B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. | |
| UA109271C2 (uk) | Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми | |
| UA116196C2 (uk) | Синтетичний міметик апеліну для лікування серцевої недостатності | |
| MX2014000363A (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| PH12014501176A1 (en) | Anticoagulant reversal agents | |
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| EA201490883A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ | |
| BR112012016894A2 (pt) | lactobacilos com ação antioxidante. | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| EA201591773A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| MX368474B (es) | Uso de benralizumab para mejorar síntomas de asma. | |
| IL272683A (en) | Systems and methods for mitigating the effects of changes in blood volume in tissues to aid in the diagnosis of percolation or leakage of blood in animal tissue | |
| EA201270315A1 (ru) | Новые формы полициклического соединения | |
| HK1215069A1 (zh) | 肺中的細菌負荷位置的確定 | |
| IN2014DN08312A (es) | ||
| HUE042708T2 (hu) | Szívelégtelenség diagnosztika | |
| EA201391772A1 (ru) | Способ диагностики ревматоидного артрита | |
| MX2015017535A (es) | Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4. |